Publications by authors named "A Franco-Moreno"
Article Synopsis
- - Venous thromboembolism (VTE) is a common issue that requires ongoing management, including assessing recurrence risk, treatment duration, and bleeding risk, as well as identifying long-term complications.
- - The Spanish Society of Internal Medicine’s VTE Group created a consensus document to provide updated recommendations on these management aspects, including risk factors for recurrence and bleeding.
- - The document emphasizes long-term follow-up for VTE patients by reviewing literature and guidelines, offering guidance on extended anticoagulant treatment duration, therapy types, and dosages.
Article Synopsis
- The study investigates the role of DNA methylation changes in individuals who developed long-lasting post-COVID pain after being hospitalized for COVID-19 compared to those who did not develop such symptoms.
- Researchers analyzed saliva samples from 279 COVID-19 survivors, noting that 39.1% of them reported experiencing persistent pain, particularly localized pain and headaches.
- The results revealed no significant differences in DNA methylation levels associated with the angiotensin-converting enzyme 2 promoter between those with and without post-COVID pain, suggesting methylation may not be a key factor in the development of long-lasting symptoms.
Patients with thrombotic antiphospholipid syndrome (APS) are at high risk for recurrent thrombosis, and indefinite anticoagulation is recommended. Patients with APS merit indefinite anticoagulation, and vitamin K antagonists (VKAs) have historically been the standard treatment. Direct oral anticoagulants (DOACs) present an appealing alternative to VKAs.
View Article and Find Full Text PDFEffect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial.
Front Med (Lausanne)
July 2024
Introduction And Objectives: Corticosteroids are among the drugs demonstrating a mortality benefit for coronavirus disease 2019 (COVID-19). The RECOVERY trial highlighted that dexamethasone reduced 28-day mortality for hospitalized COVID-19 patients requiring either supplemental oxygen or mechanical ventilation. It is noted that approximately 30% of COVID-19 patients, initially presenting with mild symptoms, will advance to acute respiratory distress syndrome (ARDS), especially those with detectable laboratory markers of inflammation indicative of disease progression.
View Article and Find Full Text PDFDNA Methylation Levels of the ACE2 Promoter Are Not Associated with Post-COVID-19 Symptoms in Individuals Who Had Been Hospitalized Due to COVID-19.
Microorganisms
June 2024
It is known that SARS-CoV-2 can translocate via membrane ACE2 exopeptidase into the host cells, and thus hypomethylation of ACE2 possibly upregulates its expression, enhancing the risk of SARS-CoV-2 infection. This study investigated if DNA methylation levels of the ACE2 promoter are associated with the development of post-COVID-19 symptomatology in a cohort of COVID-19 survivors who had been previously hospitalized. Non-stimulated saliva samples were obtained from 279 (51.
View Article and Find Full Text PDF